BIT Capital’s Mersana Therapeutics MRSN Stock Holding History

BIT Capital’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-677	Closed	-$69.6K	–	159
2023 Q1	$69.6K	Buy	+677	New	+$95K	0.01%	132

Other funds holding MRSN

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BIT Capital's MRSN Position: Q2 2023 in Review

BIT Capital sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 677 shares — an estimated $69.6K sold.

BIT Capital first reported a position in MRSN in Q1 2023 and held it in 1 quarter. The position peaked at $69.6K in Q1 2023. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

BIT Capital reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
BIT Capital sold 677 Mersana Therapeutics shares in Q2 2023, an estimated $69.6K.
BIT Capital first reported a position in Mersana Therapeutics in Q1 2023 and held it in 1 quarter.
BIT Capital's Mersana Therapeutics position peaked at $69.6K in Q1 2023.
147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on BIT Capital's 13F filing for Q2 2023, filed 12 Feb 2025.